09.02.2021, 07:55

First phase of human trials for Vietnam’s Covid-19 vaccine was safe and effective against the virus

  • Most of the volunteers are in stable conditions after vaccination after being injected.
  • Nearly 400 people have registered for the second phase that is expected to last for six months.
  • Visit Vietnam Insider’s homepage for more stories.

Vietnam has completed the first phase of the human trials of Nano Covax, a homegrown COVID-19 vaccine, with the participation of 60 volunteers, the Vietnam Military Medical University said on February 8.

The last 22 volunteers received the second shots, with two receiving the 50mgc dose, and 20 getting the 75mgc dose, Vietnam News Agency reported.

Related: Vietnam’s first coronavirus vaccines will be available very soon

Experts said Nano Covax has proven safe and effective against the coronavirus SARS-CoV-2, even its new variant.

“It is time Vietnam tells the world we can do it, and in fact we have been proving ourselves in the fight against Covid-19 so far.” said Lieutenant General Do Quyet, director of Vietnam Military Medical University in Hanoi.

Most of the volunteers are in stable conditions after vaccination. Only few had light injection site pain and fever that disappeared after one to two days.

The objective of the first phase is to evaluate the safety of the vaccine, developed and manufactured by HCM City-based Nanogen Pharmaceutical Biotechnology JSC.

Nearly 400 people have registered for the second phase that is expected to last for six months, during which 560 volunteers will be injected.  

The third phase will see the engagement of more than 10,000 volunteers, beginning from August.

If the result is good, Vietnam would administer the vaccine to the public in early 2022, according to Vietnam News Agency.

The vaccine is expected to cost VND120,000 ($5.17) per dose.

A company spokesperson said the vaccine would be reasonably priced and affordable for all Vietnamese, and hopefully covered by health insurance.


Share this:

  • Facebook
  • LinkedIn
  • Reddit
  • Twitter
  • Email

Related

Top News